Compare OPBK & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OPBK | ALXO |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | United States | United States |
| Employees | 249 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 213.9M | 240.8M |
| IPO Year | 2018 | 2020 |
| Metric | OPBK | ALXO |
|---|---|---|
| Price | $14.32 | $1.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $16.50 | $3.50 |
| AVG Volume (30 Days) | 29.2K | ★ 1.4M |
| Earning Date | 04-23-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.73% | N/A |
| EPS Growth | 23.74 | ★ 26.36 |
| EPS | ★ 0.48 | N/A |
| Revenue | ★ $3,204,000.00 | N/A |
| Revenue This Year | $16.07 | N/A |
| Revenue Next Year | $11.60 | N/A |
| P/E Ratio | $29.92 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.41 | $0.41 |
| 52 Week High | $15.27 | $2.66 |
| Indicator | OPBK | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 56.38 | 41.31 |
| Support Level | $13.63 | $1.37 |
| Resistance Level | $14.95 | $1.59 |
| Average True Range (ATR) | 0.37 | 0.12 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 72.28 | 30.77 |
OP Bancorp operates its commercial community banking activities through Open Bank its wholly owned banking subsidiary. It provides commercial banking services to small and medium-sized businesses, their owners, and retail customers, with a focus on the Korean-American community. The bank currently operate twelve full service branches: nine branches across Los Angeles and Orange Counties in California, as well as one branch each in Santa Clara, California; Carrollton, Texas; and Las Vegas, Nevada. Additionally, it maintains five loan production offices located in Pleasanton, California; Atlanta, Georgia; Aurora, Colorado; Lynnwood, Washington; and Fairfax, Virginia. Substantially all its business activities are conducted through the Bank.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.